Superworth

Royalty Pharma price to book ratio RPRX

Market value divided by the book value of the company's net assets, since 2020.

Today, Nov 3, 2026
5.7×
6-year median
3.8×
Against its 6-year history
99th
percentile: 0 is its lowest day, 100 its highest
6-year range
2.1× to 5.9×
Peer median
5.9×

Royalty Pharma's price to book ratio is 5.7× as of Nov 3, 2026.

That is above its 6-year median of 3.8×, higher than on 99% of days in the last 6 years.

Over that time it ranged from 2.1× in Dec 2024 to 5.9× in Mar 2021.

The median for 10 healthcare stocks of a similar size is 5.9×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far5.6×3.5×5.7×
20253.5×2.2×3.6×
20242.2×2.1×2.8×
20232.7×2.5×4.1×
20223.9×3.9×4.6×
20214.2×3.8×5.9×
20204.4×3.2×4.4×

Against its peers

Companies in Healthcare nearest Royalty Pharma's size, closest first, today.

CompanyPrice to book ratio
RPRXRoyalty Pharma5.7×
BIIBBiogen2.0×
GEHCGE HealthCare Technologies3.3×
ONCBeOne Medicines7.8×
IQVIQVIA6.9×
ZTSZoetis10.9×
ILMNIllumina12.6×
MTDMettler-Toledo Internationaln/m
RMDResMed4.9×
WATWaters3.1×
MDLNMedlinen/m
Peer median5.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Royalty Pharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.